Therefore, based on a large population without objective cognitive impairment, consisting of completely cognitively normal (CN) and SCD individuals, this study aimed to explore associations of methylation of BIN1 promoter in peripheral blood with the susceptibility for preclinical AD or early changes of cerebrospinal fluid (CSF) AD-related biomarkers. The gene discussed is BIN1; the disease is Cognitive impairment.